Pharmacology & ToxicologybioRxivPreprint
A new efficacious Mcl-1 inhibitor maximizes bortezomib and venetoclax responsiveness in resistant multiple myeloma cells
O. S. F. Al Odat, Krishne Gowda, Sandeep Kumar Srivastava…·Manoj Kumar Pandey
This paper identifies KS18, a Mcl-1 inhibitor, as a potential treatment for multiple myeloma, showing it enhances apoptosis and overcomes resistance to bortezomib and venetoclax in resistant cells and mouse models.
1 citation